$4.28
0.05[1.18%]
At close: Apr 26
$4.28
0[0.00%]
After Hours: 4:00PM EDT
Applied Therapeutics
(NASDAQ:APLT)Applied Therapeutics Stock (NASDAQ:APLT), Analyst Ratings, Price Targets, Predictions
Applied Therapeutics Inc has a consensus price target of $10.04, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from RBC Capital, RBC Capital, and UBS on April 11, 2024, March 26, 2024, and March 15, 2024. With an average price target of $12.33 between RBC Capital, RBC Capital, and UBS, there's an implied 188.16% upside for Applied Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
UBS
Leerink Partners
Citigroup
Baird
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Applied Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/11/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 180.37% | RBC Capital | Brian Abrahams | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 03/26/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 180.37% | RBC Capital | Brian Abrahams | → $12 | Initiates | → Outperform | Get Alert |
| 03/15/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 203.74% | UBS | Esther Rajavelu | $12 → $13 | Maintains | Buy | Get Alert |
| 03/06/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 180.37% | UBS | Esther Rajavelu | $4 → $12 | Maintains | Buy | Get Alert |
| 02/22/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 180.37% | Leerink Partners | Joseph Schwartz | → $12 | Initiates | → Outperform | Get Alert |
| 02/16/2024 | APLT | Buy Now | Applied Therapeutics | $4.28 | 63.55% | Citigroup | Yigal Nochomovitz | $5 → $7 | Maintains | Buy | Get Alert |
| 04/25/2023 | APLT | Buy Now | Applied Therapeutics | $4.28 | 227.1% | Baird | Brian Skorney | $18 → $14 | Maintains | Outperform | Get Alert |
| 04/05/2023 | APLT | Buy Now | Applied Therapeutics | $4.28 | 16.82% | Citigroup | Yigal Nochomovitz | $23 → $5 | Maintains | Buy | Get Alert |
| 08/17/2022 | APLT | Buy Now | Applied Therapeutics | $4.28 | 437.38% | Citigroup | Yigal Nochomovitz | $29 → $23 | Maintains | Buy | Get Alert |
| 08/16/2022 | APLT | Buy Now | Applied Therapeutics | $4.28 | -47.43% | Barclays | Carter Gould | $2.5 → $2.25 | Maintains | Equal-Weight | Get Alert |
| 05/20/2022 | APLT | Buy Now | Applied Therapeutics | $4.28 | 577.57% | Citigroup | Yigal Nochomovitz | $30 → $29 | Maintains | Buy | Get Alert |
| 03/21/2022 | APLT | Buy Now | Applied Therapeutics | $4.28 | -41.59% | Barclays | Carter Gould | $7 → $2.5 | Maintains | Equal-Weight | Get Alert |
| 01/04/2022 | APLT | Buy Now | Applied Therapeutics | $4.28 | 63.55% | Barclays | Carter Gould | $44 → $7 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 08/27/2021 | APLT | Buy Now | Applied Therapeutics | $4.28 | 133.64% | Goldman Sachs | Madhu Kumar | — | Downgrade | Neutral → Sell | Get Alert |
FAQ
What is the target price for Applied Therapeutics (APLT)?
The latest price target for Applied Therapeutics (NASDAQ: APLT) was reported by RBC Capital on April 11, 2024. The analyst firm set a price target for $12.00 expecting APLT to rise to within 12 months (a possible 180.37% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Applied Therapeutics (APLT)?
The latest analyst rating for Applied Therapeutics (NASDAQ: APLT) was provided by RBC Capital, and Applied Therapeutics reiterated their outperform rating.
When was the last upgrade for Applied Therapeutics (APLT)?
There is no last upgrade for Applied Therapeutics.
When was the last downgrade for Applied Therapeutics (APLT)?
The last downgrade for Applied Therapeutics Inc happened on January 4, 2022 when Barclays changed their price target from $44 to $7 for Applied Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Applied Therapeutics (APLT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Applied Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Applied Therapeutics was filed on April 11, 2024 so you should expect the next rating to be made available sometime around April 11, 2025.
Is the Analyst Rating Applied Therapeutics (APLT) correct?
While ratings are subjective and will change, the latest Applied Therapeutics (APLT) rating was a reiterated with a price target of $0.00 to $12.00. The current price Applied Therapeutics (APLT) is trading at is $4.28, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.